Trump Administration Pushes to Expand Access to Unregulated Peptide Injections
The Trump administration is advancing a plan to allow pharmacies to produce popular but unvetted peptide injections, sparking debate over health safety.
POLICY WIRE — Washington, D.C. — Federal health officials are moving forward with a proposal that would permit specialty pharmacies to manufacture certain peptides, a category of largely unregulated injections that have gained significant traction among supporters of Health and Human Services Secretary Robert F. Kennedy Jr. and various wellness influencers.
The Department of Health and Human Services has submitted an interim access policy for peptides to the White House for review, according to a recent government filing. The proposal is currently under evaluation by the Office of Management and Budget, which oversees federal regulations that could carry substantial economic implications.
Peptides serve as fundamental building blocks for complex proteins, influencing hormones related to metabolism, growth, and recovery. While pharmaceutical companies have successfully brought several peptide-based medications to market for weight loss and diabetes, the substances currently under consideration have not undergone the same rigorous FDA approval process.
Despite the lack of formal approval, these products have become increasingly popular for individuals seeking energy boosts, anti-aging benefits, or muscle development. Much of the existing research on these specific peptides remains limited to animal studies, and the FDA has previously categorized substances like BPC-157 as too risky for pharmacy compounding due to potential concerns regarding contamination, allergic reactions, and tumor growth.
Secretary Kennedy has previously criticized the FDA’s stance on these products, suggesting that allowing domestic compounding pharmacies to produce them would provide a safer alternative to the gray market imports currently sourced from China. The proposed policy would likely utilize enforcement discretion, allowing pharmacies to produce these substances without the immediate threat of regulatory action.
The initiative has drawn praise from Kennedy’s allies in the wellness industry, who frame the move as a victory for medical freedom. Meanwhile, major telehealth providers, including Hims & Hers and Noom, have indicated interest in offering these products should federal access be expanded, with market analysts projecting a potential valuation between $2 billion and $3 billion.
Reporting by Policy-Wire (PW)
